Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.
Set Alert for Articles By Kate Rawson

Latest From Kate Rawson

Hereditary Angioedema Patients Urge Work On Dosing, Product Shortages

US FDA's final patient-focused drug development meeting shows high interest clinical trial enrollment.

Rare Diseases Clinical Trials

CDER Succession: Woodcock's Responsibilities Mount With No Clear #2 In Sight

If FDA decides to replace Richard Moscicki, that individual will almost automatically be seen as Janet Woodcock’s heir-apparent at CDER, should she choose to retire.

Leadership FDA

White House Opioid Report Urges Better Access To Overdose Treatment; Mandatory Prescriber Education

Pricing of anti-addiction therapies could come under more pressure from HHS if Trump Administration accepts White House commission recommendation to declare public health emergency on opioid crisis.

Neurology Drug Safety

White House Opioid Commission: Access To Drug Therapy, Coverage 'Parity' Urged

Industry's promotion and pricing behavior was a non-factor during the Christie-chaired meeting, which featured testimony from nine non-profit organizations working to resolve the opioid epidemic.

Risk Management Neurology

Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target

Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.

Biosimilars Rare Diseases

'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On

Given that 'right to try' is intended to be a patient-centered proposal, patient organizations are a strong voice in opposition, working behind the scenes to revise – or entirely exclude – the legislation as part of the user fee package. But the bill also has powerful advocates among Senate Republicans and in the Trump Administration.

Legislation FDA
See All